ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C29H53NO5
CAS番号:
分子量:
495.73
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
orlistat
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
InChI
1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
InChI key
AHLBNYSZXLDEJQ-FWEHEUNISA-N
Gene Information
human ... LIPF(8513), PNLIP(5406)
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Application
Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Biochem/physiol Actions
肥満研究に利用されるオルリスタットは、消化管内で局所的に作用してリパーゼを阻害する膵リパーゼ阻害剤です。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
溶液は完全に透明ではなく、微粒子が浮遊している場合があります。
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under オルリスタット
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
[Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].
Journal de pharmacie de Belgique, (2)(2), 67-68 (2009-09-11)
Belinda S Drew et al.
Vascular health and risk management, 3(6), 817-821 (2008-01-19)
Over the past 20 years obesity has become a worldwide concern of frightening proportion. The World Health Organization estimates that there are over 400 million obese and over 1.6 billion overweight adults, a figure which is projected to almost double
Theodosios D Filippatos et al.
Drug safety, 31(1), 53-65 (2007-12-22)
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use